Impact of celecoxib on prognosis of elderly patients with hip fracture
10.3760/cma.j.issn.1671-7368.2016.02.018
- VernacularTitle:塞来昔布对老年髋部骨折患者的预后影响探讨
- Author:
Yong WANG
;
Yejing YANG
;
Min LU
- Publication Type:Journal Article
- Keywords:
Anti-inflammatory agents,non-steroidal;
Aged;
Hipfractures;
Prognosis
- From:
Chinese Journal of General Practitioners
2016;(2):147-150
- CountryChina
- Language:Chinese
-
Abstract:
One hundred and six patients with hip fracture admitted in hospital from 2011 to 2014 were randomly divided into two groups: 52 patients received celecoxib and parecoxib ( trial group ) and 54 patients received oxycodone hydrochloride and bucinnazine (control group).On d1 and d7 after the surgery, serum levels of C-reactive protein[(26.2 ±5.4) and (10.4 ±2.8) mg/L], tumor necrosis factor-α[(40.6 ±6.1) and (31.8 ±5.3)ng/L], interleukin-6 [(22.3 ±5.7) and (18.3 ±5.2) ng/L] and prostaglandin E2 [(181.1 ± 19.4) and (153.3 ±25.8) ng/L] in trial group were all significantly lower than those in control group [(46.1 ± 14.0) and (22.1 ±5.2)mg/L, (53.2 ±5.3) and (44.6 ±7.4) ng/L, (43.3 ±11.0) and (29.1 ±8.6)ng/L, (354.3 ±105.9) and (251.0 ±37.3)ng/L, all P<005].The length of hospital stay [(11.0 ±2.2) d], rate of lung infections (6/52) and neurological abnormality (3/52) in trial group were significantly lower than those in control group [(15.5 ±1.8) d, 15/54 and 11/54, all P <0.05].The expression of CD4 +CD45 + T cells [(34.9 ±3.7)% vs.(42.5 ±4.3)%] was reduced and CD4 +Foxp3 +T cells [(19.7 ±3.8)% vs.(6.9 ± 1.5)%] was increased at 24 h after surgery in trial group compared with control group( all P<0.05).The results indicates that calecoxib can reduce the inflammatory reaction by promoting CD4 + to Foxp3 + CD4+T cell differentiation and may improve the prognosis of elderly patients with hip fracture.
